Catalyst Pharmaceuticals EPS Estimates Rise to $2.82 for 2026, Shares Up 14%
Catalyst Pharmaceuticals’ 2026 earnings per share estimates rose from $2.54 to $2.82 over the past 60 days, and 2027 estimates climbed from $2.85 to $3.20. Shares of Catalyst Pharmaceuticals have advanced 14% in the past year, with EPS surpassing consensus in each of the last four quarters by an average 35.19%.
1. EPS Estimate Revisions
Analysts have raised Catalyst Pharmaceuticals’ 2026 earnings per share forecasts from $2.54 to $2.82 over the past 60 days, reflecting improved visibility into drug sales and pipeline developments. 2027 EPS expectations similarly rose from $2.85 to $3.20 as momentum in key indications supports higher revenue projections.
2. Share Performance
Catalyst Pharmaceuticals’ stock has climbed 14% over the past year, outperforming the broader drug sector. This rally aligns with stronger-than-expected product uptake and growing investor confidence in the company’s growth trajectory.
3. Earnings Surprise Track Record
The company has exceeded consensus earnings estimates in each of the last four quarters, delivering an average positive surprise of 35.19%. Consistent beats have bolstered the stock’s performance and underpinned the upward revisions to analyst forecasts.